GH Secretagogues Act as Both Ghrelin Agonists and Allosteric Receptor Modulators

Different GH secretagogues (peptide and non-peptide) showed both direct ghrelin receptor agonism AND allosteric modulation (positive or negative) of ghrelin binding, revealing complex receptor pharmacology beyond simple agonism.

Holst, Birgitte et al.·Molecular endocrinology (Baltimore·2005·Moderate Evidencein-vitro
RPEP-01047In VitroModerate Evidence2005RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

MK-677, hexarelin, and other GH secretagogues demonstrated both direct GHS-R agonism and allosteric modulation of ghrelin binding — some enhancing (positive) and others reducing (negative) ghrelin's own receptor interaction, revealing complex biased pharmacology.

Key Numbers

How They Did This

in-vitro study on ghrp, mk-677.

Why This Research Matters

Relevant for ghrp, mk-677, receptor-signaling, peptide-design.

The Bigger Picture

Advances peptide research with clinical implications.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding MK-677, hexarelin, and other GH secretagogues demonstrated both direct GHS-R agonism and allosteric modulation of ghrelin binding — some enhancing (po
Evidence Grade:
moderate evidence.
Study Age:
Published in 2005.
Original Title:
Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
Published In:
Molecular endocrinology (Baltimore, Md.), 19(9), 2400-11 (2005)
Database ID:
RPEP-01047

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

GH Secretagogues Act as Both Ghrelin Agonists and Allosteric Receptor Modulators

What was found?

Different GH secretagogues (peptide and non-peptide) showed both direct ghrelin receptor agonism AND allosteric modulation (positive or negative) of ghrelin binding, revealing complex receptor pharmacology beyond simple agonism.

Read More on RethinkPeptides

Cite This Study

RPEP-01047·https://rethinkpeptides.com/research/RPEP-01047

APA

Holst, Birgitte; Brandt, Erik; Bach, Anders; Heding, Anders; Schwartz, Thue W. (2005). Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.. Molecular endocrinology (Baltimore, Md.), 19(9), 2400-11.

MLA

Holst, Birgitte, et al. "Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.." Molecular endocrinology (Baltimore, 2005.

RethinkPeptides

RethinkPeptides Research Database. "Nonpeptide and peptide growth hormone secretagogues act both..." RPEP-01047. Retrieved from https://rethinkpeptides.com/research/holst-2005-nonpeptide-and-peptide-growth

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.